Vet Med - Czech, 2023, 68(5):225-230 | DOI: 10.17221/43/2022-VETMED

Long-term adjuvant metronomic chemotherapy in a dog with recurrent maxillofacial osteosarcomaCase Report

MJ Jung1, KY Yoon1, YM Kim1, JS Lee1, JW Choi1, JH Kim2, HY Yoon2,3, JH Kim1,3
1 Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Gwangjin-gu, Seoul, Republic of Korea
2 Department of Veterinary Surgery, College of Veterinary Medicine, Konkuk University, Gwangjin-gu, Seoul, Republic of Korea
3 KU Center for Animal Blood Medical Science, Gwangjin-gu, Seoul, Republic of Korea

Osteosarcoma (OSA) is the most common malignant bone tumour in dogs; however, OSA of the maxilla is uncommon compared to appendicular OSA. Oral melanoma also commonly occurs in dogs with frequent distant metastasis. The role of adjuvant chemotherapy has been questioned in maxillary OSA and melanoma. A 17-year-old English Cocker Spaniel was referred with a growing mass on the right maxilla and a right lower lip mass. Osteosarcoma was diagnosed after partial maxillectomy, and the right lower lip mass was diagnosed as oral melanoma. Metronomic chemotherapy (MC) was performed, and the number of doses was tapered due to side effects at 5 weeks after initiation of MC. After 130 weeks of MC, chemotherapy was suspended due to kidney disease. After the suspension of chemotherapy, findings suggesting recurrence and metastasis were detected. The dog suddenly died 193 weeks after surgery, which was 8–14 times longer than the expected survival time. To the best of our knowledge, this is the first case report of successful long-term combination therapy, including surgery and MC, in a dog with maxillary OSA and lip melanoma. Our results show that the survival time can be greatly extended if MC is performed with proper management.

Keywords: osteosarcoma; melanoma; cyclophosphamide; piroxicam; adverse effects; survival time

Received: April 25, 2022; Accepted: May 22, 2023; Prepublished online: May 25, 2023; Published: May 29, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jung M, Yoon K, Kim Y, Lee J, Choi J, Kim J, et al.. Long-term adjuvant metronomic chemotherapy in a dog with recurrent maxillofacial osteosarcoma. Vet Med - Czech. 2023;68(5):225-230. doi: 10.17221/43/2022-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chan CM, Frimberger AE, Moore AS. Incidence of sterile hemorrhagic cystitis in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide: 55 cases (2009-2015). J Am Vet Med Assoc. 2016 Dec 15;249(12):1408-14. Go to original source... Go to PubMed...
    2. Coyle VJ, Rassnick KM, Borst LB, Rodriguez CO Jr, Northrup NC, Fan TM, Garrett LD. Biological behaviour of canine mandibular osteosarcoma. A retrospective study of 50 cases (1999-2007). Vet Comp Oncol. 2015 Jun;13(2):89-97. Go to original source... Go to PubMed...
    3. Eichstadt LR, Moore GE, Childress MO. Risk factors for treatment-related adverse events in cancer-bearing dogs receiving piroxicam. Vet Comp Oncol. 2017 Dec;15(4):1346-53. Go to original source... Go to PubMed...
    4. Farcas N, Arzi B, Verstraete FJ. Oral and maxillofacial osteosarcoma in dogs: A review. Vet Comp Oncol. 2014 Sep;12(3):169-80. Go to original source... Go to PubMed...
    5. Gaspar TB, Henriques J, Marconato L, Queiroga FL. The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field. Vet Comp Oncol. 2018 Mar;16(1):2-11. Go to original source... Go to PubMed...
    6. Harper A, Blackwood L. Toxicity of metronomic cyclophosphamide chemotherapy in a UK population of cancer-bearing dogs: A retrospective study. J Small Anim Pract. 2017 Apr;58(4):227-30. Go to original source... Go to PubMed...
    7. LeBlanc AK, Atherton M, Bentley RT, Boudreau CE, Burton JH, Curran KM, Dow S, Giuffrida MA, Kellihan HB, Mason NJ, Oblak M, Selmic LE, Selting KA, Singh A, Tjostheim S, Vail DM, Weishaar KM, Berger EP, Rossmeisl JH, Mazcko C. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021 Jun;19(2):311-52. Go to original source... Go to PubMed...
    8. London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G. Impact of toceranib/piroxicam/cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: A multi-institutional study. PLoS One. 2015 Apr 29;10(4):e0124889. Go to original source... Go to PubMed...
    9. Matsuyama A, Schott CR, Wood GA, Richardson D, Woods JP, Mutsaers AJ. Evaluation of metronomic cyclophosphamide chemotherapy as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy. J Am Vet Med Assoc. 2018 Jun 1;252(11):1377-83. Go to original source... Go to PubMed...
    10. Mouser P, Cole A, Lin TL. Maxillary osteosarcoma in a prairie dog (Cynomys ludovicianus). J Vet Diagn Invest. 2006 May;18(3):310-2. Go to original source... Go to PubMed...
    11. Penel N, Adenis A, Bocci G. Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol. 2012 Apr;82(1):40-50. Go to original source... Go to PubMed...
    12. Poon AC, Matsuyama A, Mutsaers AJ. Recent and current clinical trials in canine appendicular osteosarcoma. Can Vet J. 2020 Mar;61(3):301-8.
    13. Romiti A, Cox MC, Sarcina I, Di Rocco R, D'Antonio C, Barucca V, Marchetti P. Metronomic chemotherapy for cancer treatment: A decade of clinical studies. Cancer Chemother Pharmacol. 2013 Jul;72(1):13-33. Go to original source... Go to PubMed...
    14. Selmic LE, Lafferty MH, Kamstock DA, Garner A, Ehrhart NP, Worley DR, Withrow SJ, Lana SE. Outcome and prognostic factors for osteosarcoma of the maxilla, mandible, or calvarium in dogs: 183 cases (1986-2012). J Am Vet Med Assoc. 2014 Oct 15;245(8):930-8. Go to original source... Go to PubMed...
    15. Silveira TL, Veloso ES, Goncalves INN, Costa RF, Rodrigues MA, Cassali GD, Del Puerto HL, Pang LY, Argyle DJ, Ferreira E. Cyclooxygenase-2 expression is associated with infiltration of inflammatory cells in oral and skin canine melanomas. Vet Comp Oncol. 2020 Dec;18(4):727-38. Go to original source... Go to PubMed...
    16. Stevenson VB, Klahn S, LeRoith T, Huckle WR. Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies. Front Vet Sci. 2023 Jan 6;9:1046636. Go to original source... Go to PubMed...
    17. Szewczyk M, Lechowski R, Zabielska K. What do we know about canine osteosarcoma treatment? Review. Vet Res Commun. 2015 Mar;39(1):61-7. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content